Dantrolene is a therapeutic agent of significant interest in the medical community, particularly in anesthesia and neurology (12). Initially introduced in the 1960s, dantrolene has since become a crucial drug in the management of malignant hyperthermia (MH), a rare but potentially fatal condition triggered by specific anesthetic agents (5). However, its role extends beyond anesthesia to several clinical scenarios.
Malignant hyperthermia is an acute pharmacogenetic disorder characterized by a hypermetabolic state in skeletal muscles triggered by volatile anesthesia and depolarizing muscle relaxants (11). Hallmark symptoms include a rapid rise in body temperature, tachycardia, hypercapnia, and severe muscle rigidity (11). Dantrolene’s mechanism of action is pivotal in mitigating these symptoms by binding to the ryanodine receptor (RyR1) in skeletal muscle, inhibiting the release of calcium ions from the sarcoplasmic reticulum (1, 2). This action counteracts the hypermetabolic state, controlling excessive muscle contractions and preventing the escalation of hyperthermia (2). The introduction of dantrolene has dramatically reduced the mortality rate associated with MH, transforming a once-fatal condition into a manageable medical emergency (10).
In addition to its primary role in anesthesia, dantrolene treats various muscle spasticity disorders (12). Conditions such as multiple sclerosis, cerebral palsy, and spinal cord injuries can result in chronic spasticity, impairing mobility and quality of life (9). Dantrolene reduces intracellular calcium concentrations in skeletal muscles, alleviating spasticity and improving motor function. Clinical studies have demonstrated its efficacy in decreasing muscle tone and enhancing physical capabilities in patients with these conditions (12, 3). However, the potential side effects, including generalized muscle weakness and hepatotoxicity, require careful patient monitoring and dosage adjustments (12, 3).
Beyond its neuromuscular applications related to anesthesia and degenerative neuromuscular diseases, dantrolene has demonstrated potential in neuroprotection, particularly in neurodegenerative diseases like Alzheimer’s and amyotrophic lateral sclerosis, where dysregulated calcium homeostasis is believed to contribute to disease pathogenesis (13, 14). Dantrolene’s ability to modulate intracellular calcium levels has prompted investigations into its potential to slow disease progression (14). Preclinical studies have yielded promising results, demonstrating that dantrolene can mitigate neuronal damage and improve cell survival in models of neurodegeneration (13). Although clinical trials are in the early stages, the neuroprotective effects of dantrolene represent a promising avenue for future therapeutic strategies.
Dantrolene is also helpful in cardiac surgery, particularly in managing postoperative muscle rigidity and hypermetabolic states (11). Cardiac surgeries involving cardiopulmonary bypass can lead to complications such as postoperative shivering and increased oxygen consumption (4). Dantrolene attenuates muscle contractions, minimizing these adverse effects, improving recovery, and reducing metabolic strain (12). Additionally, dantrolene plays a role in managing
neuroleptic malignant syndrome (NMS), a rare but life-threatening reaction to antipsychotic medications (7). Its muscle relaxant properties provide symptomatic relief and prevent the progression of NMS, making it a critical intervention in emergency psychiatric care (7).
Dantrolene is well-regarded for its therapeutic benefits, but its risks require thorough evaluation (6). Long-term use of this medication carries a significant risk of hepatotoxicity, necessitating regular liver function tests to identify early indications of damage promptly (6). Moreover, dantrolene-induced muscle weakness can impair patients’ ability to engage in physical activity and rehabilitation, potentially extending recovery periods (3). The sedative effects, while sometimes beneficial, can complicate its usage, particularly in patients with existing neuromuscular conditions (6). A comprehensive risk-benefit analysis is essential to determine the appropriateness of dantrolene therapy, especially in long-term treatments or for individuals with multiple health conditions.
The versatile applications of dantrolene underscore its significance in contemporary medical practice. From its lifesaving role in managing malignant hyperthermia to its potential in treating muscle spasticity, neurodegenerative diseases, and postoperative complications, dantrolene exemplifies the evolution of a therapeutic agent from a specialized intervention to a versatile clinical tool. Ongoing research and clinical trials will likely continue to expand its therapeutic scope, offering new avenues for managing complex medical conditions. Considering its benefits and risks will ensure that dantrolene remains valuable in medical care and improves patient outcomes across diverse clinical settings.
References
1. Fruen, B. R., Mickelson, J. R., & Louis, C. F. (1997). Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. The Journal of biological chemistry, 272(43), 26965–26971. https://doi.org/10.1074/jbc.272.43.26965
2. Gaburjakova, J., & Gaburjakova, M. (2023). Molecular Aspects Implicated in Dantrolene Selectivity with Respect to Ryanodine Receptor Isoforms. International journal of molecular sciences, 24(6), 5409. https://doi.org/10.3390/ijms24065409
3. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Dantrolene. [Updated 2017 Jan 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548144/
4. Jeon, J., Song, S., Kim, M. C., Kim, K. M., & Lee, S. (2014). The effect of long-term oral dantrolene on the neuromuscular action of rocuronium: a case report. Korean Journal of anesthesiology, 66(2), 153–156. https://doi.org/10.4097/kjae.2014.66.2.153
5. Kaufmann, J., & Kung, E. (2019). Factors Affecting Cardiovascular Physiology in Cardiothoracic Surgery: Implications for Lumped-Parameter Modeling. Frontiers in surgery, 6, 62. https://doi.org/10.3389/fsurg.2019.00062
6. Krause, T., Gerbershagen, M.U., Fiege, M., Weißhorn, R., & Wappler, F. (2004). Dantrolene – A review of its pharmacology, therapeutic use and new developments. Anaesthesia, 59: 364-373. https://doi.org/10.1111/j.1365-2044.2004.03658.x
7. Ngo, V., Guerrero, A., Lanum, D., Burgett-Moreno, M., Fenati, G., Barr, S., & Neeki, M. M. (2019). Emergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using Dantrolene. Clinical practice and cases in emergency medicine, 3(1), 16–23. https://doi.org/10.5811/cpcem.2018.11.39667
8. Ratto, D., & Joyner, R. W. (2023). Dantrolene. [Updated 2023 Apr 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535398/
9. Selph, S. S., Skelly, A. C., Wasson, N., et al. (2021). Physical Activity and the Health of Wheelchair Users: A Systematic Review in Multiple Sclerosis, Cerebral Palsy, and Spinal Cord Injury [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Oct. Available from: https://www.ncbi.nlm.nih.gov/books/NBK574867/
10. Toyota, Y., Kondo, T., Shorin, D., Sumii, A., Kido, K., Watanabe, T., Otsuki, S., Kanzaki, R., Miyoshi, H., Yasuda, T., Horikawa, Y. T., Mukaida, K., & Tsutsumi, Y. M. (2023). Rapid Dantrolene Administration with Body Temperature Monitoring Is Associated with Decreased Mortality in Japanese Malignant Hyperthermia Events. BioMed research international, 2023, 8340209. https://doi.org/10.1155/2023/8340209
11. Watt, S., & McAllister, R. K. (2023). Malignant Hyperthermia. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430828/
12. Yang, H. S., Choi, J. M., In, J., Sung, T. Y., Kim, Y. B., & Sultana, S. (2023). Current clinical application of dantrolene sodium. Anesthesia and pain medicine, 18(3), 220–232. https://doi.org/10.17085/apm.22260
13. Zhang, W., Zhao, X., Bhuiyan, P., Liu, H., & Wei, H. (2024). Neuroprotective effects of dantrolene in neurodegenerative disease: Role of inhibition of pathological inflammation. Journal of anesthesia and translational medicine, 3(2), 27–35. https://doi.org/10.1016/j.jatmed.2024.04.002